Abstract |
The use of nano-carriers has been shown to improve the delivery and efficacy of chemotherapeutic agents in cancer patients. Recent studies suggest that decoration of the surface of nano-carriers with various targeting moieties may further improve the overall therapeutic efficacy. In this study, we compared the therapeutic efficacy of Doxil(®) (commercial doxorubicin-loaded liposomes) and that of Doxil(®) conjugated with anti-CD30 antibodies (CD30-targeted Doxil(®)) in treating anaplastic large cell lymphoma (ALCL), a type of T-cell lymphoma characterized by a high CD30 expression. Compared to Doxil(®), the CD30-targeted Doxil(®) showed a significantly higher binding affinity to ALCL cells (5.3% versus 27%, p = 0.005) and a lower inhibitory concentration at 50% (IC50) in-vitro (32.6 μg/mL versus 12.6 μg/mL, p = 0.006). In a SCID mouse xenograft model, CD30-targeted Doxil(®) inhibited tumor growth more significantly than the unconjugated formulation; specifically, tumors in mice treated with CD30-targeted Doxil(®) were significantly smaller than those in mice treated with Doxil(®) (average, 117 mm(3) versus 270 mm(3), p = 0.001) at 18 days after the tumors were inoculated. Our findings have provided the proof-of-principle of using CD30-targeted nano-carriers to treat cancers that are characterized by a high level of CD30 expression, such as ALCL.
|
Authors | Ommoleila Molavi, Xiao-Bing Xiong, Donna Douglas, Norm Kneteman, Satoshi Nagata, Ira Pastan, Quincy Chu, Afsaneh Lavasanifar, Raymond Lai |
Journal | Biomaterials
(Biomaterials)
Vol. 34
Issue 34
Pg. 8718-8725
(Nov 2013)
ISSN: 1878-5905 [Electronic] Netherlands |
PMID | 23942212
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Ki-1 Antigen
- liposomal doxorubicin
- Polyethylene Glycols
- Doxorubicin
|
Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Cell Line, Tumor
- Disease Models, Animal
- Doxorubicin
(analogs & derivatives, therapeutic use)
- Ki-1 Antigen
(immunology)
- Lymphoma, Large-Cell, Anaplastic
(drug therapy)
- Male
- Mice
- Mice, SCID
- Nanoparticles
(chemistry)
- Polyethylene Glycols
(therapeutic use)
|